

ASX Announcement

13 December 2024

Oncosil completes \$1 million Share Purchase Plan (SPP)

13 December 2024, Melbourne: Oncosil Medical Ltd (ASX: OSL) (the **Company** or **OSL**) is pleased to announce the successful completion of the Share Purchase Plan (**SPP**) announced on 28 October 2024, and which closed on 6 December 2024.

Under the Prospectus dated 6 November 2024, eligible shareholders were able to apply for up to A\$30,000 worth of New Shares at \$0.01 per share, together with 1 New Option for every 1 New Share issued under the SPP. The New Options are exercisable at any time until and including their expiry date of 20 December 2027 at an exercise price of \$0.015 each.

The issue of New Shares and New Options under the SPP Offer and SPP Shortfall Commitment was approved by shareholders at the Extraordinary General Meeting held on 11 December 2024. The SPP raised a total of \$1 million. The total amount raised comprised 69 million New Shares and 69 million New Options issued to existing Eligible Shareholders under the SPP Offer and 31 million New Shares and 31 million New Options were issued under the SPP Shortfall Commitment. The New Shares and New Options are due to be issued on 13 December 2024, and to commence trading on 16 December 2024.

The funds raised from the SPP will be applied to further investment in OSL's Macquarie Park manufacturing facility, funding of clinical trials, together with payment for other working capital costs and costs of the offer.

Managing Director and CEO, Nigel Lange said: “We would like to thank our shareholders for their continued support in OncoSil. The SPP raise enables us to focus our efforts on commercial activities, completing important clinical trials that enable label expansion and permit increased market access.”

Indicative SPP Issue Timetable¹	Date
Issue of New Shares and Options under SPP Offer	13 December 2024
Expected normal trading of New Shares and Options under SPP Offer	16 December 2024

1. Dates / times are indicative and subject to change. All times / dates are in reference to AEDT.

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

<p>Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043</p>	<p>Mr. Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254</p>	<p>Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699</p>
---	---	--

For personal use only

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>